Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation

References

• Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am. J. Gastroenterol.99(4), 750–759 (2004).
   PubMedGoogle Scholar
• Shah N, Locke GR 3rd, Meek P, Chitkara D, Talley NJ. Ambulatory care for constipation in the United States, 1997–2004. Am. J. Gastroenterol.101(S2), S220 (2006).
   Google Scholar
• Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation – is the work-up worth the cost? Dis. Colon Rectum40(3), 280–286 (1997).
   PubMed Web of Science ®Google Scholar
• Brook R, Kleinman N, Melkonian A, Baran R. Cost of illness for constipation: medical, pharmacy, and work absence costs in employees with or without constipation. Am. J. Gastroenterol.101(S2), S408 (2006).
   Google Scholar
• Kleinman N, Brook R, Melkonian A, Baran R. Assessment of work absences associated with constipation. Am. J. Gastroenterol.101(Suppl. 2), S409 (2006).
   Google Scholar
• Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics23(5), 461–476 (2005).
   PubMed Web of Science ®Google Scholar
• An evidence-based approach to the management of chronic constipation in North America. Am. J. Gastroenterol.100(Suppl. 1), S1–S4 (2005).
   PubMedGoogle Scholar
• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130(5), 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M. Chronic constipation. N. Engl. J. Med.349(14), 1360–1368 (2003).
   PubMed Web of Science ®Google Scholar
• Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastronenterol. Clin. N. Am.36(3), 687–711 (2007).
   PubMedGoogle Scholar
• Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation.Am. J. Gastroenterol.94(3), 609–615 (1999).
   PubMedGoogle Scholar
• Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment. Pharmacol. Ther.25(5), 599–608 (2007).
   PubMed Web of Science ®Google Scholar
• Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am. J. Gastroenterol.100(4), 936–971 (2005).
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am. J. Gastroenterol.100(Suppl. 1), S5–S21 (2005).
   PubMedGoogle Scholar
• Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastronenterol. Clin. N. Am.34(2), 319–335, viii (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Morita T, Iwamoto T. Diversity of Cl(-) channels. Cell Mol. Life Sci.63(1), 12–24 (2006).
   PubMed Web of Science ®Google Scholar
• Zifarelli G, Pusch M. CLC chloride channels and transporters: a biophysical and physiological perspective. Rev. Physiol. Biochem. Pharmacol.158, 23–76 (2007).
   PubMedGoogle Scholar
• Lipecka J, Bali M, Thomas A, Fanen P, Edelman A, Fritsch J. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am. J. Physiol.282(4), C805–816 (2002).
   PubMed Web of Science ®Google Scholar
• Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J. Clin. Gastroenterol.41(4), 345–351 (2007).
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am. J. Physiol.287(5), C1173–C1183 (2004).
   PubMed Web of Science ®Google Scholar
• Ueno R, Osama H, Habe T, Engelke K, Patchen ML. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration wihtout altering serum electrolyte levels. Gastroenterology126(4 Suppl. 2), A298 (2004) (Abstract).
   Web of Science ®Google Scholar
• Perentesis G, Crawford D, Engelke K, Osama H, Ueno R. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Neurogastroenterol. Motility17(5), 625–626 (2005) (Abstract).
   Google Scholar
• Bassil AK, Borman RA, Jarvie EM et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br. J. Pharmacol.154(1), 126–135 (2008).
   PubMed Web of Science ®Google Scholar
• Amitiza® (lubiprostone), prescribing information. Sucampo Pharmaceuticals Inc. (2007).
   Google Scholar
• Crawford D, Perentesis G, Engelke K, Kawai R, Ueno R. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator after a single oral dose in multiple animal species. Am. J. Gastroenterol.100(S9), S330 (2005) (Abstract).
   Google Scholar
• Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol. Motility17(4), 626 (2005) (Abstract).
   Google Scholar
• Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol.290(5), G942–G947 (2006).
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment. Pharmacol. Ther.25(11), 1351–1361 (2007).
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol.103(1), 170–177 (2008).
   PubMed Web of Science ®Google Scholar
• Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am. J. Gastroenterol.100(s9), S324–325 (2005) (Abstract).
   Google Scholar
• Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator, for the treatment of constipation: safety and primary efficacy. Am. J. Gastroenterol.100(S9), S328–S329 (2005) (Abstract).
   Web of Science ®Google Scholar
• Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology126(4 Suppl. 2), A100 (2004) (Abstract).
   Web of Science ®Google Scholar
• Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am. J. Gastroenterol.100(S9), S331 (2005) (Abstract).
   Web of Science ®Google Scholar
• Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology130(4 Suppl. 2), A317 (2006) (Abstract).
   Web of Science ®Google Scholar
• Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects. Gastroenterology130(4 Suppl. 2), A189 (2006) (Abstract).
   Web of Science ®Google Scholar
• Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology130(4 Suppl. 2), A188 (2006) (Abstract).
   PubMed Web of Science ®Google Scholar
• Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects. Gastroenterology130(4 Suppl. 2), A322 (2006) (Abstract).
   Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. pharmacol. Ther.27(8), 685–696 (2008).
   PubMed Web of Science ®Google Scholar
• Johanson JF, Wahle A, Ueno R. Efficacy and safety of lubiprostone in a subgroup of constipation patients diagnosed with irritable bowel syndrome with constipation (IBS-C). Am. J. Gastroenterol.101(S2), S491 (2006) (Abstract).
   Google Scholar
• Drossman DA, Chey WD, Panas R, Wahle A, Scott C, Ueno R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology132(7), 2586–2587 (2007) (Abstract).
   Web of Science ®Google Scholar
• Chey WD, Drossman DA, Scott C, Panas R, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology134(4 Suppl. 1), A215 (2008) (Abstract).
   PubMedGoogle Scholar
• Chey WD, Saad R, Panas R, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology134(4 Suppl. 1), A401 (2008) (Abstract).
   Web of Science ®Google Scholar
• Chey WD, Drossman DA, Scott C, Panas R, Ueno R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology134(4 Suppl. 1), A28 (2008) (Abstract).
   Web of Science ®Google Scholar
• Drossman DA, Chey WD, Scott C, Panas R, Ueno R. Health-related quality of life in adults with irritable bowel syndrome with constipation: results of a combined analysis of two Phase 3 studies with lubiprostone. Gastroenterology134(4 Suppl. 1), A469 (2008) (Abstract).
   Google Scholar
• Sprenger C, Copa A, Morganroth J, Panas R, Ueno R. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiographic results. Gastroenterology132(4 Suppl. 2), A325 (2007) (Abstract).
   Web of Science ®Google Scholar
• Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, does not affect serum electrolyte balance in elderly and nonelderly patients with chronic idiopathic constipation. Gastroenterology132(4 Suppl. 2), A191 (2007) (Abstract).
   Web of Science ®Google Scholar
• Ueno R, Wahle A, Rivera E. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone. Am. J. Gastroenterol.101(s2), s489 (2006) (Abstract).
   Web of Science ®Google Scholar
• Engelke K, Harris S, Roerig B, Ueno R. Effect of lubiprpstone, a novel type-2 chloride channel (ClC-2) activator, in pregnant rhesus monkeys. Gastroenterology132(4 Suppl. 2), A534 (2007) (Abstract).
   Google Scholar
• Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Blikslager AT. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am. J. Physiol. Gastrointest. Liver Physiol.292(2), G647–656 (2007).
   PubMed Web of Science ®Google Scholar